| | 760937-92-6 Basic information More.. |
| Product Name: | Teneligliptin | | Synonyms: | teneligliptin;3-[[(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl]carbonyl]thiazolidine;Methanone,[(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl]-3-thiazolidinyl-;Teneligptin WS;[(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone;API (Teneligliptin free base);Teliglietin;Teneligliptin (MP-513) | | CAS: | 760937-92-6 | | MF: | C22H30N6OS | | MW: | 426.58 | | EINECS: | | | Mol File: | 760937-92-6.mol |  |
Use
Teneligliptin was approved in September 2012 in Japan for the treatment of patients with Type 2 diabetes mellitus (T2DM). Teneligliptin is a member of the dipeptidyl peptidase 4 (DPP-4) inhibitor class of antidiabetes agents. DPP-4 is an enzyme that degrades GLP-1, a 30-amino acid peptide that is secreted in response to food intake. GLP-1 stimulates insulin secretion and inhibits glucagon secretion, which leads to lower levels of plasma glucose. Teneligliptin is one of a growing numbers of DPP-4 inhibitors to be approved worldwide. The discovery of teneligliptin was guided by structure-based design, with a key element being binding of the phenyl group in the S2 pocket, which not only increases potency for DPP-4, but also improves selectivity versus DPP-8 and DPP- 9. Teneligliptin is a potent inhibitor of DPP-4 in the enzyme inhibition assay (IC50=0.37 nM).
- Teneligliptin
-
- US $0.00-0.00 / KG
- 2025-04-04
- CAS:760937-92-6
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1ton
- Teneligliptin
-
- US $0.00-0.00 / kg
- 2024-11-26
- CAS:760937-92-6
- Min. Order: 1kg
- Purity: 99%, Single impurity＜0.1
- Supply Ability: 1 ton
- Teneligliptin
-
- US $0.00-44.00 / mg
- 2024-11-19
- CAS:760937-92-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
|
760937-92-6
Recommend Suppliers |
|